Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Mar;10(3):446-53.
doi: 10.1097/JTO.0000000000000423.

MiR-205 and MiR-375 microRNA assays to distinguish squamous cell carcinoma from adenocarcinoma in lung cancer biopsies

Affiliations

MiR-205 and MiR-375 microRNA assays to distinguish squamous cell carcinoma from adenocarcinoma in lung cancer biopsies

Santosh Patnaik et al. J Thorac Oncol. 2015 Mar.

Abstract

Introduction: Identification of adenocarcinoma (AC) and squamous cell carcinoma (SCC) histology of non-small-cell lung cancer (NSCLC) in biopsies is clinically important but can be inaccurate by routine histopathologic examination. We quantify this inaccuracy at a cancer center, and evaluate the utility of a microRNA-based method to histotype AC/SCC in biopsies.

Methods: RNA was extracted from tissue sections with greater than 90% tumor content that were macro- or micro-dissected from formalin-fixed, paraffin-embedded biopsy specimens. MicroRNAs in RNA from the biopsies and from resected tumors were quantified by TaqMan reverse transcription-polymerase chain reaction assays and normalized against the RNU6B housekeeping RNA. Publicly available microRNA expression datasets were examined.

Results: NSCLC subtyping of small biopsy specimens by routine histopathologic examination either failed or mistyped the histology of 21% of 190 cases. Using 77 resectates, an reverse transcription-polymerase chain reaction-based assay of microRNAs miR-21, miR-205, and miR-375 was developed to identify AC and SCC subtypes of NSCLC. This method identified the AC/SCC histotypes of 25 biopsies with an accuracy of 96%, and correctly histotyped all 12 cases for which the histology had been mistyped by routine histopathologic examination of the biopsy. Examination of publicly available datasets identified miR-205 and miR-375 as microRNAs with the best ability to histotype AC and SCC, and that levels of the two microRNAs in AC or SCC are unaffected by the pathologic stage of the tumor or the age or race of the patient.

Conclusions: Histotypic microRNA assays can aid the subtyping of NSCLC biopsies as AC or SCC by standard histopathologic methods.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: None to disclose

Figures

Figure 1
Figure 1. Histotypic microRNAs to distinguish lung squamous cell carcinoma (SCC) and adenocarcinoma (AC) identified in analyses of data from the Cancer Genome Atlas
Count per million microRNAs in primary AC (n = 334, black) and SCC (n = 300, gray) tumor or tumor-adjacent normal lung tissues (n = 79, white) for 10 of the 12 microRNAs identified in the analyses are depicted as mean and 95% confidence interval values.
Figure 2
Figure 2. Correlation between small RNA quantifications obtained by reverse transcription (RT)-PCR using two amounts of tissue RNA
Measurements obtained using 0.2 ng RNA of 14 resected lung cancers of U6B and miR-21, -205 and -375 as quantification cycle (Cq) values, and of miR-205 relative to U6B and miR-21 (Lebanony score), or only U6B (miR-205 ΔCqU6B) are plotted against those obtained with 5 ng RNA. The Pearson correlation coefficient (r) with 95% confidence interval, and the linear regression line generated with the least squares fitting technique are also shown.
Figure 3
Figure 3. Expression of miR-205 in lung squamous cell carcinoma (SCC) and adenocarcinoma (AC) resectates
Reverse transcription (RT)-PCR was used to quantify miR-205 relative to U6B and miR-21 (Lebanony score), or only U6B (miR-205 ΔCqU6B) in 5 ng RNA for 49 AC and 28 SCC cases. For each type of measurement, panel A shows dot-plots of individual values along with histology-specific group means and standard deviations; panel B shows receiver operating characteristic curves, along the area under curve (AUC) with 95% confidence interval, for the miR-205 measurements to discriminate SCC from AC; and, panel C shows the measurement values in terms of molarity along with linear regression lines and their slopes (m) and Y intercepts (b) determined by the least squares fitting technique. Molarity equivalent of the Lebanony score could be determined for only 56 of the total 77 cases.
Figure 4
Figure 4. Expression of miR-205 and miR-375 in lung squamous cell carcinoma (SCC) and adenocarcinoma (AC) resectates
Reverse transcription (RT)-PCR was used to quantify miR-205 relative to U6B and miR-21 (Lebanony score), and of miR-375 relative to U6B (miR-375 ΔCqU6B) in 5 ng RNA for 49 AC (gray) and 28 SCC (black) cases. Dotted lines indicate the median and standard deviation (SD) values of miR-375 ΔCqU6B and Lebanony scores of the AC cases with scores >2.5.

Comment in

Similar articles

Cited by

References

    1. Scagliotti G, Hanna N, Fossella F, et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist. 2009;14:253–263. - PubMed
    1. Gressett SM, Shah SR. Intricacies of bevacizumab-induced toxicities and their management. Ann Pharmacother. 2009;43:490–501. - PubMed
    1. Travis WD, Brambilla E, Riely GJ. New Pathologic Classification of Lung Cancer: Relevance for Clinical Practice and Clinical Trials. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2013 - PubMed
    1. Sigel CS, Moreira AL, Travis WD, et al. Subtyping of non-small cell lung carcinoma: a comparison of small biopsy and cytology specimens. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer. 2011;6:1849–1856. - PubMed
    1. Rekhtman N, Ang DC, Sima CS, et al. Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens. Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc. 2011;24:1348–1359. - PubMed

MeSH terms